Citizens downgrades Foghorn Therapeutics stock rating on drug discontinuation
Citizens downgraded Foghorn Therapeutics (FHTX) to Market Perform after it and Eli Lilly discontinued the FHD-909 drug candidate due to poor efficacy. Shares fell 18% to $2.88, extending a 34% YTD decline. Citizens cited lack of near-term catalysts, noting shares trade at a 26% premium to cash reserves. InvestingPro analysis suggests undervaluation, while Stifel lowered its price target to $5.00 but maintained a Buy rating.
How this was made
The 30-second read
Why it matters
The discontinuation eliminates a near‑term revenue catalyst, prompting a downgrade and share price decline.
Market read
The downgrade and trial failure are fresh, material news for FHTX, likely prompting short‑term sell pressure.
What to watch
Potential cash runway of $168 million and possible future collaborations could mitigate short‑term downside.
Background
Foghorn Therapeutics announced the termination of its partnership with Eli Lilly on the SMARCA2 inhibitor FHD-909 after disappointing trial data.
Ticker impact
Citizens downgraded Foghorn Therapeutics to Market Perform after the company and Eli Lilly discontinued the SMARCA2 inhibitor FHD-909, causing the stock to fall to $2.88.
downward pressure as investors price in the loss of a key asset and reduced pipeline momentum
Analyst downgrade combined with a failed drug candidate is a fresh, material catalyst for a biotech micro‑cap, prompting immediate sell pressure.
Market effects
May weigh on other chromatin‑targeting biotech stocks as investors reassess similar programs.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the company can successfully pivot to its pre‑clinical pipeline, the stock could be undervalued at current levels.
Key entities
- companyFoghorn Therapeutics
Biotech firm developing epigenetic therapies (ticker FHTX).
- companyEli Lilly
Pharmaceutical partner in the discontinued collaboration.
- analystCitizens
Research firm that downgraded FHTX to Market Perform.
